Skip to main content
Top
Published in: Cancer Chemotherapy and Pharmacology 5/2019

01-05-2019 | Original Article

Determination of melphalan in human plasma by UPLC–UV method

Authors: Liusheng Huang, Vincent Cheah, Danna Chan, Florence Marzan, Christopher C. Dvorak, Francesca T. Aweeka, Janel Long-Boyle

Published in: Cancer Chemotherapy and Pharmacology | Issue 5/2019

Login to get access

Abstract

It is desirable to develop a fast method for quantification of melphalan due to its instability. Here we report a method for quantification of melphalan (MPL) in human plasma using a UPLC–PDA system. Briefly, 50 µL plasma sample was mixed with 25 µL internal standard (2500 ng/mL acetylmelphalan in methanol) and 25 µL 20% trichloroacetic acid, and centrifuged at 21,000 g (15,000 rpm) at 4 °C for 3 min. The supernatant (5 µL) was injected onto an Acquity™ BEH C18 LC column (2.1 × 50 mm, 1.7 µm) and eluted with 25 mM NH4AC (pH 4.7)—acetonitrile in a gradient mode at a flow rate of 0.6 mL/min. The column kept at 40 ± 5 °C and the autosampler kept at 4 ± 5 °C. The detector set at 261 nm, and sampling rate was 40points/sec. The retention times were typically 2.11 min for melphalan and 2.38 min for the internal standard. Total run time is 4 min per sample. Calibration range was 100–40,000 ng/mL. The lower limit of quantification was 100 ng/mL. The method was validated based on the FDA guidelines, and applied to a clinical pharmacokinetic study in pediatric patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Krumbhaar EB, Krumbhaar HD (1919) The blood and bone marrow in Yelloe Cross Gas (Mustard Gas) poisoning: changes produced in the bone marrow of fatal cases. J Med Res 40(3):497–508 493PubMedPubMedCentral Krumbhaar EB, Krumbhaar HD (1919) The blood and bone marrow in Yelloe Cross Gas (Mustard Gas) poisoning: changes produced in the bone marrow of fatal cases. J Med Res 40(3):497–508 493PubMedPubMedCentral
2.
go back to reference Hall AG, Tilby MJ (1992) Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies. Blood Rev 6(3):163–173CrossRefPubMed Hall AG, Tilby MJ (1992) Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies. Blood Rev 6(3):163–173CrossRefPubMed
3.
go back to reference Mizuno K, Dong M, Fukuda T et al (2018) Population pharmacokinetics and optimal sampling strategy for model-based precision dosing of melphalan in patients undergoing hematopoietic stem cell transplantation. Clin Pharmacokinet 57(5):625–636CrossRefPubMed Mizuno K, Dong M, Fukuda T et al (2018) Population pharmacokinetics and optimal sampling strategy for model-based precision dosing of melphalan in patients undergoing hematopoietic stem cell transplantation. Clin Pharmacokinet 57(5):625–636CrossRefPubMed
4.
go back to reference Bergel F, Stock JA (1954) Cyto-active amino-acid and peptide derivatives. Part I. Substituted phenylalanines. J Chem Soc 0(0):2409–2417CrossRef Bergel F, Stock JA (1954) Cyto-active amino-acid and peptide derivatives. Part I. Substituted phenylalanines. J Chem Soc 0(0):2409–2417CrossRef
5.
go back to reference Boschmans J, De Bruijn E, Van Schil P, Lemiere F (2013) Analysis of novel melphalan hydrolysis products formed under isolated lung perfusion conditions using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 27(7):835–841CrossRefPubMed Boschmans J, De Bruijn E, Van Schil P, Lemiere F (2013) Analysis of novel melphalan hydrolysis products formed under isolated lung perfusion conditions using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 27(7):835–841CrossRefPubMed
6.
go back to reference Ehrsson H, Lonroth U (1982) Degradation of melphalan in aqueous solutions—influence of human albumin binding. J Pharm Sci 71(7):826–827CrossRefPubMed Ehrsson H, Lonroth U (1982) Degradation of melphalan in aqueous solutions—influence of human albumin binding. J Pharm Sci 71(7):826–827CrossRefPubMed
7.
go back to reference Reece PA, Hill HS, Green RM et al (1988) Renal clearance and protein binding of melphalan in patients with cancer. Cancer Chemother Pharmacol 22(4):348–352CrossRefPubMed Reece PA, Hill HS, Green RM et al (1988) Renal clearance and protein binding of melphalan in patients with cancer. Cancer Chemother Pharmacol 22(4):348–352CrossRefPubMed
8.
go back to reference Nath CE, Shaw PJ, Montgomery K, Earl JW (2007) Population pharmacokinetics of melphalan in paediatric blood or marrow transplant recipients. Br J Clin Pharmacol 64(2):151–164CrossRefPubMedPubMedCentral Nath CE, Shaw PJ, Montgomery K, Earl JW (2007) Population pharmacokinetics of melphalan in paediatric blood or marrow transplant recipients. Br J Clin Pharmacol 64(2):151–164CrossRefPubMedPubMedCentral
9.
go back to reference Gouyette A, Hartmann O, Pico JL (1986) Pharmacokinetics of high-dose melphalan in children and adults. Cancer Chemother Pharmacol 16(2):184–189CrossRefPubMed Gouyette A, Hartmann O, Pico JL (1986) Pharmacokinetics of high-dose melphalan in children and adults. Cancer Chemother Pharmacol 16(2):184–189CrossRefPubMed
10.
go back to reference Nath CE, Trotman J, Tiley C et al (2016) High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation. Br J Clin Pharmacol 82(1):149–159CrossRefPubMedPubMedCentral Nath CE, Trotman J, Tiley C et al (2016) High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation. Br J Clin Pharmacol 82(1):149–159CrossRefPubMedPubMedCentral
11.
go back to reference Nath CE, Shaw PJ, Trotman J et al (2010) Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy. Br J Clin Pharmacol 69(5):484–497CrossRefPubMedPubMedCentral Nath CE, Shaw PJ, Trotman J et al (2010) Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy. Br J Clin Pharmacol 69(5):484–497CrossRefPubMedPubMedCentral
12.
go back to reference Nath CE, Shaw PJ, Montgomery K, Earl JW (2005) Melphalan pharmacokinetics in children with malignant disease: influence of body weight, renal function, carboplatin therapy and total body irradiation. Br J Clin Pharmacol 59(3):314–324CrossRefPubMedPubMedCentral Nath CE, Shaw PJ, Montgomery K, Earl JW (2005) Melphalan pharmacokinetics in children with malignant disease: influence of body weight, renal function, carboplatin therapy and total body irradiation. Br J Clin Pharmacol 59(3):314–324CrossRefPubMedPubMedCentral
13.
go back to reference Pinguet F, Joulia JM, Martel P, Grosse PY, Astre C, Bressolle F (1996) High-performance liquid chromatographic assay for melphalan in human plasma. Application to pharmacokinetic studies. J Chromatogr B Biomed Appl 686(1):43–49CrossRefPubMed Pinguet F, Joulia JM, Martel P, Grosse PY, Astre C, Bressolle F (1996) High-performance liquid chromatographic assay for melphalan in human plasma. Application to pharmacokinetic studies. J Chromatogr B Biomed Appl 686(1):43–49CrossRefPubMed
14.
go back to reference Poujol S, Pinguet F, Mougenot P et al (2004) Quantitation of melphalan in human plasma by liquid chromatography and solid phase extraction: Application to pharmacokinetic study. J Liq Chromatogr R T 27(2):301–313CrossRef Poujol S, Pinguet F, Mougenot P et al (2004) Quantitation of melphalan in human plasma by liquid chromatography and solid phase extraction: Application to pharmacokinetic study. J Liq Chromatogr R T 27(2):301–313CrossRef
15.
go back to reference Springolo V, Borella F, Finardi GP, Gatti MT, Coppi G (1989) High-performance liquid chromatographic determination of m-bis(chloroethyl)aminophenyl-l-alanine in plasma. J Chromatogr 490(1):224–229CrossRefPubMed Springolo V, Borella F, Finardi GP, Gatti MT, Coppi G (1989) High-performance liquid chromatographic determination of m-bis(chloroethyl)aminophenyl-l-alanine in plasma. J Chromatogr 490(1):224–229CrossRefPubMed
16.
go back to reference Chang SY, Alberts DS, Melnick LR, Walson PD, Salmon SE (1978) High-pressure liquid chromatographic analysis of melphalan in plasma. J Pharm Sci 67(5):679–682CrossRefPubMed Chang SY, Alberts DS, Melnick LR, Walson PD, Salmon SE (1978) High-pressure liquid chromatographic analysis of melphalan in plasma. J Pharm Sci 67(5):679–682CrossRefPubMed
17.
go back to reference Huang L, Lizak P, Dvorak CC, Aweeka F, Long-Boyle J (2014) Simultaneous determination of fludarabine and clofarabine in human plasma by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 960:194–199CrossRefPubMedPubMedCentral Huang L, Lizak P, Dvorak CC, Aweeka F, Long-Boyle J (2014) Simultaneous determination of fludarabine and clofarabine in human plasma by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 960:194–199CrossRefPubMedPubMedCentral
18.
go back to reference Clinical Pharmacology Quanlity Assurance (Cpqa) Program. CPQA Guidelines for chromatographic method development and validation based on (and including) FDA guidelines dated May 2001, Version 4.0 (2012). 1–52 (2012) Clinical Pharmacology Quanlity Assurance (Cpqa) Program. CPQA Guidelines for chromatographic method development and validation based on (and including) FDA guidelines dated May 2001, Version 4.0 (2012). 1–52 (2012)
19.
go back to reference Us Department of Health and Human Services, Food and Drug Administration. Guidance for industry: bioanalytical method validation. May 2001 Us Department of Health and Human Services, Food and Drug Administration. Guidance for industry: bioanalytical method validation. May 2001
20.
go back to reference Sparidans RW, Martens I, Valkenburg-Van Iersel LB, Den Hartigh J, Schellens JH, Beijnen JH (2011) Liquid chromatography-tandem mass spectrometric assay for the PARP-1 inhibitor olaparib in combination with the nitrogen mustard melphalan in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 879(21):1851–1856CrossRefPubMed Sparidans RW, Martens I, Valkenburg-Van Iersel LB, Den Hartigh J, Schellens JH, Beijnen JH (2011) Liquid chromatography-tandem mass spectrometric assay for the PARP-1 inhibitor olaparib in combination with the nitrogen mustard melphalan in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 879(21):1851–1856CrossRefPubMed
21.
go back to reference Huang L, Marzan F, Jayewardene AL, Lizak PS, Li X, Aweeka FT (2009) Development and validation of a hydrophilic interaction liquid chromatography-tandem mass spectrometry method for determination of isoniazid in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 877(3):285–290CrossRefPubMed Huang L, Marzan F, Jayewardene AL, Lizak PS, Li X, Aweeka FT (2009) Development and validation of a hydrophilic interaction liquid chromatography-tandem mass spectrometry method for determination of isoniazid in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 877(3):285–290CrossRefPubMed
Metadata
Title
Determination of melphalan in human plasma by UPLC–UV method
Authors
Liusheng Huang
Vincent Cheah
Danna Chan
Florence Marzan
Christopher C. Dvorak
Francesca T. Aweeka
Janel Long-Boyle
Publication date
01-05-2019
Publisher
Springer Berlin Heidelberg
Published in
Cancer Chemotherapy and Pharmacology / Issue 5/2019
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-019-03786-6

Other articles of this Issue 5/2019

Cancer Chemotherapy and Pharmacology 5/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine